 |
|
Effects of Alzheimer's Disease and Normal Aging on Cerebrospinal Fluid Norepinephrine Responses to Yohimbine and Clonidine
Elaine R. Peskind, MD;
Dane Wingerson, MD;
Sharon Murray, RN;
Marcella Pascualy, MD;
Dorcas J. Dobie, MD;
Pascal Le Corre, PharmD, PhD;
Roger Le Verge, PharmD, PhD;
Richard C. Veith, MD;
Murray A. Raskind, MD
Arch Gen Psychiatry. 1995;52(9):774-782.
Abstract
| |
Background
The resting cerebrospinal fluid (CSF) norepinephrine concentration is unchanged or even increased in patients with Alzheimer's disease (AD). These in vivo findings appear to be inconsistent with the postmortem locus ceruleus neuronal loss that is reported in patients with AD.
Methods
The effects of AD and advanced age on central nervous system noradrenergic status were estimated by comparing CSF norepinephrine concentrations following the administration of yohimbine hydrochloride, clonidine hydrochloride, and placebo in outpatients with AD and older and young normal subjects. Levels of yohimbine, its metabolite 11-hydroxy-yohimbine, and clonidine were measured in CSF and plasma samples. Behavioral responses were quantified by rating the Tension, Excitement, and Anxiety items on the Brief Psychiatric Rating Scale.
Results
Yohimbine-induced increases of CSF norepinephrine concentrations were greater in both patients with AD and normal older subjects than in normal young subjects. Clonidine-induced decreases of CSF norepinephrine concentrations did not differ among groups. Behavioral arousal following the administration of yohimbine was greater in patients with AD than in the other groups.
Conclusions
Central nervous system noradrenergic responsiveness is enhanced in normal older subjects, and this age effect is retained in patients with AD. Behavioral sensitivity to increased central nervous system noradrenergic activity is enhanced in patients with AD.
Author Affiliations
From the Geriatric Research Education and Clinical Center, Seattle (Wash)/American Lake Veterans Affairs Medical Center (Drs Peskind, Pascualy, Dobie, Veith, and Raskind and Ms Murray), the Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle (Drs Peskind, Wingerson, Pascualy, Dobie, Veith, and Raskind and Ms Murray), and the Faculte des Sciences Pharmaceutiqueset Biologiques, University of Rennes I (France) (Drs Le Corre and Le Verge).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Cognitive Enhancement Therapy for a Model of Down Syndrome
Wiseman
Sci Transl Med 2009;1:7ps9-7ps9.
FULL TEXT
The Role of Norepinephrine in the Behavioral and Psychological Symptoms of Dementia
Herrmann et al.
J. Neuropsychiatry Clin. Neurosi. 2004;16:261-276.
ABSTRACT
| FULL TEXT
Prazosin Reduces Trauma-Related Nightmares in Older Men with Chronic Posttraumatic Stress Disorder
Peskind et al.
J Geriatr Psychiatry Neurol 2003;16:165-171.
ABSTRACT
Cholinergic deficits contribute to behavioral disturbance in patients with dementia
Minger et al.
Neurology 2000;55:1460-1467.
ABSTRACT
| FULL TEXT
Cerebrospinal Fluid Corticotropin-Releasing Hormone in Healthy Humans: Effects of Yohimbine and Naloxone
Vythilingam et al.
J. Clin. Endocrinol. Metab. 2000;85:4138-4145.
ABSTRACT
| FULL TEXT
Increased Plasma Norepinephrine Response to Yohimbine in Elderly Men
Petrie et al.
Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2000;55:155M-159.
ABSTRACT
| FULL TEXT
Stimulation of amyloid precursor protein synthesis by adrenergic receptors coupled to cAMP formation
Lee et al.
Proc. Natl. Acad. Sci. USA 1997;94:5422-5426.
ABSTRACT
| FULL TEXT
|
